lunes, 12 de marzo de 2012

Spontaneous disclosure of BRCA1/2 genetic te... [Eur J Hum Genet. 2012] - PubMed - NCBI

Spontaneous disclosure of BRCA1/2 genetic te... [Eur J Hum Genet. 2012] - PubMed - NCBI

Eur J Hum Genet. 2012 Feb 29. doi: 10.1038/ejhg.2012.37. [Epub ahead of print]

Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study.


1] Institut Paoli-Calmettes, Marseille, France [2] INSERM, U912, Marseille, France [3] Aix-Marseille Université, U912, Marseille, France [4] IRD, U912, Marseille, France.


The aim of this study was to examine the patterns of disclosure of BRCA1/2 genetic test results to employers by unaffected carriers. In a national prospective cohort study on unaffected BRCA1/2 mutation carriers, disclosure to employers was assessed prospectively, using self-administered questionnaires, up to 2 years after their test results were delivered by cancer geneticists. Kaplan-Meier curves and Cox-regression analysis were used to assess the factors associated with time to disclosure to the employer. Mean age of the 146 women BRCA1/2 carriers who were employed when their test results were delivered was 37.1 years (range: 19-57). At the end of the second year of follow-up, 47 of them (32.2%) had disclosed their results to their employers; median time to disclosure was 6 months. Reasons spontaneously expressed were first to inform the employer that medical surveillance/surgery was necessary for cancer risk management although these carriers did not actually have cancer. After multivariate adjustment on age, women with a lower educational level (HRadj=2.00, P=0.026) and those who had undergone prophylactic surgery during the 2 years of follow-up (HRadj=2.18, P=0.019) had disclosed their BRCA status to their employers earlier and more frequently. One-third of the female carriers not affected by breast/ovarian cancer disclosed their BRCA1/2 genetic test results spontaneously to their employers, mainly to inform them that they were disease-free but required medical surveillance or a surgical intervention to reduce the risk of cancer.European Journal of Human Genetics advance online publication, 29 February 2012; doi:10.1038/ejhg.2012.37.
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario